Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648011 | Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg | PHASE1 | COMPLETED | 44 | — | — | Aug 1, 2003 | Sep 1, 2003 | Apr 24, 2024 | 1 | United States |
| NCT00649441 | Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg | PHASE1 | COMPLETED | 60 | — | — | Aug 1, 2003 | Sep 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Accuretic™ Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Accuretic™ Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...